title: [Development of peptidic MERS-CoV entry inhibitors].
abstract: In 2012, a new SARS-like coronavirus emerged in the Middle East, namely the Middle East respiratory syndrome coronavirus (MERS-CoV). It has caused outbreaks with high mortality. During infection of target cell, MERS-CoV S protein S1 subunit binds to the cellular receptor (DPP4), and its S2 subunit HR1 and HR2 regions intact with each other to form a stable six-helix bundle to mediate the fusion between virus and target cell membranes. Hence, blocking the process of six-helix bundle formation can effectively inhibit MERS-CoV entry into the target cells. This review focuses on the recent advance in the development of peptidic entry inhibitors targeting the MERS-CoV S2 subunit.
authors.forename: Shuai
authors.initials: S
authors.lastname: Xia
authors.forename: Qian
authors.initials: Q
authors.lastname: Wang
authors.forename: Shu-wen
authors.initials: SW
authors.lastname: Liu
authors.forename: Lu
authors.initials: L
authors.lastname: Lu
authors.forename: Shi-bo
authors.initials: SB
authors.lastname: Jiang
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D018352:Coronavirus Infections / Q000188:drug therapy; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D065207:Middle East Respiratory Syndrome Coronavirus / Q000187:drug effects* / Q000502:physiology; D010455:Peptides / Q000494:pharmacology; D064370:Spike Glycoprotein, Coronavirus / Q000378:metabolism; D053586:Virus Internalization / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D010455:Peptides; D064370:Spike Glycoprotein, Coronavirus; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4